Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.57 USD | -0.15% |
|
+6.08% | +9.70% |
07-09 | RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating | MT |
07-01 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 8.3B | |
+7.46% | 100B | |
+8.42% | 42.34B | |
-13.04% | 32.76B | |
+80.04% | 29.46B | |
-10.92% | 16.31B | |
+1.93% | 14.39B | |
-6.77% | 12.23B | |
+177.16% | 10.47B | |
+1.72% | 8.97B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Transcript : Intra-Cellular Therapies, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-12-2021 06